You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. IGF OT IGF A STAGE BASED MOBILE INTERVENTION FOR SUBSTANCE USE DISORDERS IN PRIMARY CARE N DA POP SEPTEMBER FEBRUARY BASE AWARD

    SBC: Pro-Change Behavior Systems Inc            Topic: NIDA

    Not Available

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. IGF OT IGF VALIDATION OF MOBILE TECHNOLOGIES FOR CLINICAL ASSESSMENT

    SBC: Pro-Change Behavior Systems Inc            Topic: NCI

    Not Available

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. IGF OT IGF FY IWIN NAVIGATING YOUR PATH TO WELL BEING SBIR PHASE II BASE AWARD PERIOD OF PERFORMANCE

    SBC: Pro-Change Behavior Systems Inc            Topic: NIDA

    Not Available

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. New Assays for Expression Profiling of MicroRNAs

    SBC: Nawgen, LLC            Topic: 172

    DESCRIPTION provided by applicant MicroRNAs miRNAs are involved in many diverse biological processes and a single miRNA can modulate the expression of hundreds of gene targets Changes in miRNA expression could have profound biological impacts leading to a variety of human diseases To date most miRNA expression profiling studies have relied on microarrays or high throughput RNA sequencing ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Rational design of small interfering RNA for genome-wide target knockdown

    SBC: Nawgen, LLC            Topic: 172

    DESCRIPTION provided by applicant RNA interference RNAi is a small RNA guided gene silencing process within living cells The RNAi technique is widely used in both biological research and clinical applications because it has the ability to knockdown essentially any gene of interest However one major unresolved issue in RNAi studies is non specific gene silencing It is well known that in ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Activate Silent and Cryptic Intact Fungal SM Gene Clusters through FACs for Novel Antibiotics Discovery

    SBC: Intact Genomics Inc.            Topic: NIAID

    DESCRIPTION provided by applicant There is societal need for new therapeutic agents in our arsenal of defenses against bacterial and fungal pathogens many of which are increasingly resistant to existing antibiotics Filamentous fungi are considered promising resources for the development of novel bioactive compounds because of their great potential to produce various kinds of secondary metabol ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Therapeutic Role of Inter-alpha Inhibitors in Wound Healing

    SBC: PROTHERA BIOLOGICS, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant Wound healing is an intricately regulated process broadly characterized by phases of inflammation proliferation and remodeling Imbalances in any one of these phases can result in inadequate healing scar formation or in the development of chronic wounds such as diabetic ulcers Diabetic ulcers are responsible for the majority of lower extremity amputations ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Optimized IL2-based Therapy for Type 1 Diabetes

    SBC: APT THERAPEUTICS, INC.            Topic: NIDDK

    DESCRIPTION provided by applicant Type diabetes is an immune mediated disease in which insulin producing beta cells are destroyed resulting in life long dependence on exogenous insulin The number of patients being diagnosed is increasing each year particularly in the very young Despite advances in glucose monitoring and insulin delivery there is a compelling need to identify therapies th ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Low-dose IL-2-based Immunomodulatory Therapy for PAH

    SBC: APT THERAPEUTICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Despite evidence that inflammatory mechanisms initiate and complicate pathophysiology in pulmonary arterial hypertension PAH no strategies have been developed to target the inflammatory cells involved Moreover it has been known for years that autoimmune diseases are associated with certain forms of PAH Hence novel therapy is urgently needed to attenuate ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Jerry the Bear: A Robotic Platform for At-Home Therapy and Education for Children with Type 1 Diabetes

    SBC: Sproutel            Topic: 200

    DESCRIPTION provided by applicant The goal of this SBIR Phase I application from Sproutel is to develop a curriculum for providing expert educational content on diabetes self management to be delivered via principles of game based learning in an appealing teddy bear robotic character designed for young children diagnosed with type diabetes mellitus Type diabetes T D affects approximately ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government